desmoid tumor
Conditions
Interventions
None listed
Sponsors
Department of Orthopaedic Surgery, Nara Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: We included all reports examining effectiveness and toxicity of TKIs such as imatinib, sorafenib, anlotinib, pazopanib or nilotinib or low-dose or conventional chemotherapeutic agents such as methotrexate (MTX) plus vinblastine (VBL) or vinorelbine (VNL), anthracycline based regimens, or pegylated liposomal doxorubicin for progressive DT. We included studies involving human subjects and articles that used clearly defined disease control rates or progression-free survival as an outcome. Only the articles published from January 1, 1995 in English were included.
Exclusion criteria
Exclusion criteria: We excluded studies with unclear indication of outcomes, review articles, isolated case reports or case series including fewer than five patients, non-English abstracts, and conference abstracts. We excluded studies that did not specify progressive disease as the inclusion criterion or those that reported effectiveness and toxicity of antihormonal therapies or NSAIDs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival, reduction of tumor size by the modified Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1), disease control rate, and adverse events evaluated by Common Terminology Criteria for Adverse Events (CTCAE; version 5.0). | — |
Countries
Japan
Contacts
Public ContactShinji Tsukamoto
Nara Medical University Department of Orthopaedic Surgery
Outcome results
None listed